<DOC>
	<DOC>NCT00002325</DOC>
	<brief_summary>To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts &lt; 250 cells/mm3 who are living in the coccidioidal endemic area.</brief_summary>
	<brief_title>A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common</brief_title>
	<detailed_description>Patients are randomized to receive either fluconazole or placebo daily.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Coccidioidomycosis</mesh_term>
	<mesh_term>Coccidiosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Documented HIV infection. CD4 count &lt; 250 cells/mm3. No active coccidioidomycosis or other fungal disease requiring systemic antifungal therapy. Residence in area considered to be endemic for Coccidioides immitis. Consent of parent or guardian if under legal age of consent. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Unable to take oral medication. Positive serum cryptococcal antigen. Concurrent Medication: Excluded: Systemic antifungal therapy. Patients with the following prior conditions are excluded: History of hypersensitivity to azole or imidazole compounds. Prior Medication: Excluded: Systemic antifungal agents within 2 weeks prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Mycoses</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Coccidioidomycosis</keyword>
</DOC>